posted on 2024-06-06, 08:03authored byEmmanuel
T. Adeniyi, Marco Kruppa, Stefania De Benedetti, Kevin C. Ludwig, Violetta Krisilia, Tobias R. Wassenberg, Melissa Both, Tanja Schneider, Thomas J. J. Müller, Rainer Kalscheuer
About 100,000 deaths are attributed annually to infections
with
methicillin-resistant Staphylococcus aureus (MRSA)
despite concerted efforts toward vaccine development and clinical
trials involving several preclinically efficacious drug candidates.
This necessitates the development of alternative therapeutic options
against this drug-resistant bacterial pathogen. Using the Masuda borylation-Suzuki
coupling (MBSC) sequence, we previously synthesized and modified naturally
occurring bisindole alkaloids, alocasin A, hyrtinadine A and scalaradine
A, resulting in derivatives showing potent in vitro and in vivo antibacterial efficacy. Here, we report
on a modified one-pot MBSC protocol for the synthesis of previously
reported and several undescribed N-tosyl-protected
bisindoles with anti-MRSA activities and moderate cytotoxicity against
human monocytic and kidney cell lines. In continuation of the mode
of action investigation of the previously synthesized membrane-permeabilizing
hit compounds, mechanistic studies reveal that bisindoles impact the
cytoplasmic membrane of Gram-positive bacteria by promiscuously interacting
with lipid II and membrane phospholipids while rapidly dissipating
membrane potential. The bactericidal and lipid II-interacting lead
compounds 5c and 5f might be interesting
starting points for drug development in the fight against MRSA.